<DOC>
	<DOCNO>NCT01517802</DOCNO>
	<brief_summary>The purpose study collect follow-up safety data participant complete abiraterone acetate study maximum duration 6 year .</brief_summary>
	<brief_title>A Study That Provides Long-term Safety Follow-up Examines Long-term Exposure Abiraterone Acetate</brief_title>
	<detailed_description>This nonrandomized ( individual assign chance study treatment ) , open-label ( individual know identity study treatment ) , long-term safety follow-up study abiraterone acetate approximately 300 patient complete abiraterone acetate clinical study . Patients must receive least 3 month treatment abiraterone acetate low-dose corticosteroid , base investigator assessment , may benefit continued treatment . This study consist screen period follow open-label treatment continue abiraterone acetate access . The patient continue abiraterone acetate low-dose corticosteroid dose regimen receive previous abiraterone acetate clinical study investigator determine patient longer receive benefit sponsor terminate study . Patients withdraw study alternative access ( eg , patient-assistance program commercial source abiraterone acetate ) available feasible . Each cycle treatment 28 day . Investigators monitor assess patient response treatment progression accord routine practice clinically indicate determine whether continued treatment abiraterone acetate warrant . No efficacy data collect . Safety monitor throughout study maximum duration 6 year . End-of-study assessment perform least 30 day last dose abiraterone upon early withdrawal .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Currently participate abiraterone acetate clinical study consider complete receive least 3 month treatment abiraterone acetate tablet . Medical condition require hospitalization . Any condition situation , opinion investigator , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Metastatic castration-resistant prostate cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Low-dose corticosteroid treatment</keyword>
	<keyword>Long-term access</keyword>
</DOC>